Clinical Trial Update: A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Pharmacodynamics, and Efficacy of P-CD19CD20-ALLO1 in Participants With Severe, Treatment-refractory Systemic Lupus Erythematosus (SLE) [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating the safety, tolerability, cellular kinetics, pharmacodynamics, and efficacy of the cellular therapy P-CD19CD20-ALLO1 in adults…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• P-CD19CD20-ALLO1

Snippet

Sponsor: Genentech, Inc. | Conditions: Systemic Lupus Erythematosus | Phase 1 | Status: NOT_YET_RECRUITING